Although technical caveats are still a matter of concern to detect antibodies targeting this complicated antigen, using very diverse approaches, evidence is accumulating against the confirmation of KIR4.1 as a relevant MS autoantigen. The gene discussed is KCNJ10; the disease is myeloid sarcoma.